Summary: During this session, we review progress in several areas of advanced development and their impact on readiness for large scale manufacturing.
Summary: In this informative interview with Phacilitate, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.
Summary: In this ebook, we bring you expert insights into the advantages that various cellular starting materials have, with a particular focus on human induced pluripotent stem cells (iPSCs).
Summary: Catalent and RegMedNet showcase how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. This feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.
Summary: How can using iPSCs as starting materials help with transforming cell therapies into standard care? This infographic highlights the key features of iPSCs as starting materials, from donor consent through to commercial innovation.
Summary: This podcast focuses on the specialized needs of manufacturing cell therapies at scale and how Custom Manufacturing Organizations are stepping in to drive process efficiencies and standardization.
Summary: In this presentation, our Expert discusses efforts underway at Catalent to accelerate the path to clinic for iPSC-based therapies.
Summary: Scientists are leading a well-funded drive to adapt technology for solid tumors while making the whole process much more economical for patients and payers.
Summary: At Catalent, we implement innovative manufacturing and fill & finish methodologies to accelerate the path to commercial for MSCs and other allogeneic modalities.
Summary: Experts discuss the changing experience from the last quarter of a century in the pathway to patients, and how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing.
Summary: Experts discuss a breadth of analytical methodologies, fill & finish approaches and manufacturing designs to accelerate CAR-T therapies to commercial readiness phase in this on-demand webinar.
Summary: Both cell therapy innovators and manufacturing organizations are employing novel technologies and methodologies to adapt to an accelerated and evolving clinical landscape
Summary: This roundtable is a must-watch for early and late-stage cell therapy innovator companies who are considering a manufacturing partnership.
Summary: CAR-T cell therapies require expertise in process development to successfully scale-up manufacturing. Working with an integrated partner like Catalent gives you the ability to manufacture at clinical and commercial scale efficiently and effectively for both autologous and allogeneic cell therapies.
Summary: Catalent has made significant investments in the cell and gene therapy space with strategic acquisitions and commitment to grow and innovate.
Summary: Catalent has made significant investments in capacity expansions to meet the growing demand of our customers.
Summary: This executive summary details why maintaining a strategic view of the production-scale from early stages of development helps accelerate the time-to-market, drives process efficiencies, and reduces costs.
Summary: The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities…
Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
Summary: Catalent Cell & Gene Therapy is a premier partner for innovators across the entire field of advanced biotherapeutics. Explore our development and manufacturing capabilities for allogeneic and autologous cell therapies, viral vector-based…
Summary: In this on-demand webinar from the 2020 CPhI Festival of Pharma, panelists discuss innovative technologies and their adoption for cell and gene therapies.
Summary: Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.
Summary: In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies and the various solutions available for commercial scale-up of advanced therapeutics
Summary: This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.
Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness Using “Manufacturing by Design” Methodology
Summary: Allogeneic T-cell therapies are moving towards having breakthrough therapies available for market launch.
Summary: Learn about Catalent’s journey into the Cell and Gene therapy space, overcoming challenges, and the company’s commitment to its partners.